Engineered adenosine kinase variants
AssigneeCodexis, Inc.
InventorsStephanie Marie Forget, Marissa Greene MacAvoy, Simon Ng, Nicholas Porter, Leann Quertinmont Teadt, Jonathan Vroom
Life of this patent
Estimating the term…
Abstract
The present disclosure provides engineered adenosine kinase polypeptides, and recombinant polynucleotides encoding the engineered adenosine kinases. The present disclosure further provides method of using the engineered adenosine kinases.
Claims146
An engineered adenosine kinase comprising an amino acid sequence having at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to a reference sequence corresponding to amino acid residues 12-321 of an even-numbered SEQ ID NO. of SEQ ID NOs:
- 2-1142, 1194-1808, and 1818-2124, or to a reference sequence corresponding to an even-numbered SEQ ID NO. of SEQ ID NOs:
- 2-1142, 1194-1808, and 1818-2124, wherein the amino acid sequence comprises one or more substitutions relative to the reference sequence corresponding to amino acid residues 12-321 of SEQ ID NO:
- 2, 90, 254, 370, 734, 896, 1196, 1366, 1382, 1464, 1568, 1616, 1668, 1766, 1826, 1918, or 1942 or relative to the reference sequence corresponding to SEQ ID NO:
- 2, 90, 254, 370, 734, 896, 1196, 1366, 1382, 1464, 1568, 1616, 1668, 1766, 1826, 1918, or 1942.
A method of producing an engineered adenosine kinase polypeptide, comprising culturing a host cell of claim 112 or 119 under suitable culture conditions such that the engineered adenosine kinase polypeptide is produced.
Dependencies are inferred from the claim text.